MedTrace Logo

Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen

NCT07055893 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2025-07-09

No results posted yet for this study

Summary

To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after post-exposure prophylaxis (PEP) vaccination, and to confirm its satisfying safety profile in the pediatric and adult population in a PEP schedule

Conditions

  • Rabies (Healthy Volunteers)

Interventions

BIOLOGICAL

Rabies vaccine

Receiving five doses of rabies vaccine manufactured by Sinovac using the "Essen" PEP schedule

BIOLOGICAL

Verorab®

Receiving five doses of marketed rabies vaccine manufactured by Sanofi using the "Essen" PEP schedule

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Ume Sughra, Dr. · Director Research, Al-Shifa Research Centre; Professor of Public Health, Al-Shifa Trust Eye Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-01-30
Completion
2027-01-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07055893 on ClinicalTrials.gov